Network Genomic Medicine cancer information system (NGMcis)

The NGM gathers a lot of data that is relevant for the molecular diagnosis of tumor material. Requirements for this are established in the NGM due to regulations for the integrated health care. A complete patient follow up after the diagnosis has not been possible yet.

The NGMcis project is targeting a detailed assessment of the progress of the disease of all cancer patients that were diagnosed within the NGM, based on the data that is gathered during their decentralized treatment. NGMcis aims for an extensive evaluation of the disease and it’s course and the founding of a data interface across sectors.

Last update: 14. March 2016 , 16:06

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.